Benralizumab subcutaneous (SC) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.59 [0.52, 0.66]4 studies · 3112 participantsHigh